FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news